KNTE Kinnate Biopharma Inc.

Kinnate Biopharma Inc. is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers

$22.12  -1.40 (-5.95%)
As of 05/13/2021 15:59:55 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/03/2020
Outstanding shares:  43,486,772
Average volume:  141,564
Market cap:   $1,021,504,274
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    49705R105
ISIN:        US49705R1059
Sedol:      BLGZBT1
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.62
PS ratio:   0.00
Return on equity:   -4.49%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy